Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
BRAF Gene Mutation, BRAF wt Allele, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7 or Stage IV Cutaneous Melanoma AJCC v6 and v7
and you are
over 18
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This phase II trial studies the side effects and how well nivolumab and trametinib with or without dabrafenib work in treating patients with BRAF-mutated or wild type stage III-IV melanoma that has spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if nivolumab and trametinib with or without dabrafenib may work better in treating patients with BRAF-mutated or wild type metastatic melanoma.

Provided treatments

  • Drug: Dabrafenib
  • Other: Laboratory Biomarker Analysis
  • Biological: Nivolumab
  • Other: Pharmacological Study
  • Drug: Trametinib
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02910700. The sponsor of the trial is M.D. Anderson Cancer Center and it is looking for 51 volunteers for the current phase.
Official trial title:
A Phase II Study of the TRIplet Combination of Dabrafenib, Nivolumab, and Trametinib in Patients With Metastatic Melanoma (TRIDeNT)